OUR SOLUTIONS

Margin Assessment During Mohs Surgery

Our initial target market will be Mohs surgery, where skin cancers are treated through micrographic excision, and where the Mohs surgeon is also qualified to examine the histopathological image and make a pathological determination. SurgiVance™’s device aims to enable rapid surgical margin assessment, reducing procedure time dramatically and improving the overall patient experience.

Software Tool for Researchers

SurgiVance™’s patented software solution for digitally coloring or “staining” reflectance confocal images will be available for researchers in life sciences, dermatology, pathology, oncology, and related fields, moving investigators away from glass slides and conventional H&E staining to a faster, more cost effective digital method.

Diagnosis of Other Cancers

Once our imager is validated in Mohs surgery suites, SurgiVance™ plans to pursue approvals allowing use of its imager for surgical margin assessment of other cancers, and potentially for primary diagnosis of skin and other cancers.

Business Inquiries

SurgiVance™, Inc.
310 East 67th St.
Suite 2-91
New York, NY 10065
info@surgivance.com
+1-503-708-7078

Careers

SurgiVance™ is currently looking for engineers with expertise in opto-mechanics, deep-learning, or image recognition experience.

Please send your CV to info@surgivance.com.

Follow SurgiVance Inc. on F6S
SurgiVance is supported by the National Science Foundation and the National Institutes of Health

© 2022 SurgiVance™, Inc.
*SurgiVance™ has not yet been reviewed by the FDA and may not be used to manage patient care.